Search results for "DISEASES"

showing 10 items of 20537 documents

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct

Incidencia, factores de riesgo y significado pronóstico de la proteinuria en el trasplante renal. Valor predictivo de la proteinuria precoz sobre la …

2010

La proteinuria es el principal marcador independiente de progresión de enfermedad renal en riñones nativos. En el trasplante renal es indicativa de lesión renal a nivel glomerular y tubulointersticial, y se ha relacionado con una peor supervivencia del injerto y del paciente. No obstante, existen pocas evidencias acerca del papel pronóstico y predictivo de la proteinuria en el trasplante renal, sobre todo en lo que respecta a la proteinuria precoz y de bajo grado. En este trabajo de investigación se ha intentado profundizar en el conocimiento de la proteinuria en nuestra población trasplantada renal que incluye una elevada prevalencia de trasplantes con órganos de donantes con criterios exp…

urogenital systemFacultat de Medicina617urologic and male genital diseasesCirurgia. Ortopèdia. Oftalmologiafemale genital diseases and pregnancy complications
researchProduct

Tema 12-AP especial

2020

Tema 12-Patologia renal inflamatòria glomerular

urogenital systemUNESCO::CIENCIAS MÉDICASurologic and male genital diseasesfemale genital diseases and pregnancy complications
researchProduct

Changes in the receptor profile of the lower urinary tract in the aging male

2004

Benign prostatic hyperplasia (BPH) is one of th e most common effects of aging in men. Epidemiologists estimate that about one quarter of all men over 50 years of age suffer from BPH-derived voiding symptoms. Future demographic developments, with higher relative shares of older people, will increase the socioeconomic impact of this disease. Polder et al. (1994) calculated for the Netherlands that the treatment costs of BPH will double by 2035. Office visits for BPH related symptoms increased in the USA from 1.4 million in 1990 to 6 million in 1995, reflecting the increased public awareness of the problem and the increased desire for treatment (Kaplan et al. 1996).

urogenital systembusiness.industryAging maleUrinary systemDiseaseHyperplasiaurologic and male genital diseasesQuarter (United States coin)medicine.diseaseBladder outlet obstructionmedicinebusinessOlder peopleSocioeconomic statusDemography
researchProduct

Additional file 1: of Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Table S1. Clinical characteristics of patients at baseline and at 4-year grouped by of basal GFR. (DOCX 20 kb)

urologic and male genital diseases
researchProduct

MOESM2 of Reanalysis of Chinese Treponema pallidum samples: all Chinese samples cluster with SS14-like group of syphilis-causing treponemes

2018

Additional file 2. Mapping statistics of input read pairs mapped to the reference genomes. Sequencing reads derived from the Chinese strain SRA data were mapped to the Treponema pallidum subsp. pallidum (TPA) SS14 and Nichols reference genomes [6] and to the rabbit genome (Statistics was calculated from post-processed mappings; repetitive and homologous sequences and PCR duplicated reads were excluded from the statistics).

urologic and male genital diseases
researchProduct

MOESM1 of Reanalysis of Chinese Treponema pallidum samples: all Chinese samples cluster with SS14-like group of syphilis-causing treponemes

2018

Additional file 1. Data analysis and methods used in the reanalysis of Chinese Treponema pallidum samples.

urologic and male genital diseases
researchProduct

MOESM4 of Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain: a multicenter observational study

2017

Additional file 4. Characteristics of bladder cancer patients by hospitals.

urologic and male genital diseasesfemale genital diseases and pregnancy complications
researchProduct

MOESM3 of Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain: a multicenter observational study

2017

Additional file 3. Diagnostic tests for bladder cancer patients.

urologic and male genital diseasesfemale genital diseases and pregnancy complications
researchProduct